

References

I-83

1. Petrucci M T, Giraldo P, Corradini P, A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. *British Journal of Haematology*, 2013;(160)649–659.
2. Garrison P, Wang S, Huang H, et al. The Cost-Effectiveness of Initial Treatment of Multiple Myeloma in the U.S. With Bortezomib Plus Melphalan and Prednisone versus Thalidomide plus Melphalan and Prednisone or Lenalidomide plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment. *The Oncologist* 2013;18:27–36.
3. Ishitsuka K, Utsunomiya A, Katsuya H, et al. A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma. *Cancer Sci.* 2015;1219-1223.
4. Sullivan RJ, Ibrahim N, Lawrence DP, et al. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. *The Oncologist.* 2015;617-618.
5. Lee J, Kim BS, Park Y et al. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation. *Yonsei Med J.* 2015;1638-1642.
6. National Comprehensive Cancer Network® (NCCN) Drugs and Biologics Compendium. 2017. Bortezomib.
7. San Miguel J, Schlag R, Khuageva N, et al. Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus MelphalanPrednisone in Patients With Previously Untreated Multiple Myeloma. *J Clin Oncol.* 2013;31(4);448-455.
8. Gimsing P, Hjertner O, Abildgaard N, et al. Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial. *Bone Marrow Transplantation.* 2015;50:1306-1311.
9. Durie B, Hoering A, Abidi M, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. *The Lancet.* 2017;389(10068):519-527.
10. National Comprehensive Cancer Network (NCCN). NCCN T-Cell Lymphomas. Version 2.2018. Accessed February 8, 2018.
11. National Comprehensive Cancer Network (NCCN). NCCN B-Cell Lymphomas. Version 7.2017. Accessed February 8, 2018.
12. National Comprehensive Cancer Network (NCCN). NCCN Multiple Myeloma. Version 3.2018. Accessed February 8, 2018.

13. National Comprehensive Cancer Network (NCCN). NCCN Systemic Light Chain Amyloidosis. Version 1.2018. Accessed February 8, 2018.
14. National Comprehensive Cancer Network (NCCN). NCCN Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 1.2017. Accessed February 8, 2018.
15. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. Bortezomib.
16. MICROMEDEX®SOLUTIONS Compendia. 2018. Bortezomib. Accessed February 12, 2018.
17. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.